dc.creatordos Santos, A
dc.creatorRibeiro, ML
dc.creatorMesquita, JC
dc.creatorCarvalho-Salles, AB
dc.creatorHackel, C
dc.date2002
dc.date2014-07-30T14:48:25Z
dc.date2015-11-26T17:40:31Z
dc.date2014-07-30T14:48:25Z
dc.date2015-11-26T17:40:31Z
dc.date.accessioned2018-03-29T00:22:11Z
dc.date.available2018-03-29T00:22:11Z
dc.identifierProstate Cancer And Prostatic Diseases. Nature Publishing Group, v. 5, n. 1, n. 28, n. 31, 2002.
dc.identifier1365-7852
dc.identifierWOS:000174712500007
dc.identifier10.1038/sj/pcan/4500550
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/61932
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/61932
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1286746
dc.descriptionCYP17 gene encodes the enzyme cytochrome p450c17alpha, which mediates two steps in the steroid biosynthesis pathway. Steroid hormones are believed to play a key role in the etiology of prostate cancer. A polymorphic T-->C transition in the 5' promoter region of CYP17 creates an additional Sp1-type (CCACC box) promoter site (allele A2). We have evaluated the genotypic and allelic distribution of this polymorphism among 92 prostate cancer patients in order to assess risk by comparison with a population-based series of 200 healthy individuals from Brazil. Our results provide no evidence for an association between prostate cancer risk and CYP17 T/C polymorphism.
dc.description5
dc.description1
dc.description28
dc.description31
dc.languageen
dc.publisherNature Publishing Group
dc.publisherLondon
dc.publisherInglaterra
dc.relationProstate Cancer And Prostatic Diseases
dc.relationProstate Cancer Prostatic Dis.
dc.rightsfechado
dc.sourceWeb of Science
dc.subjectCYP17 gene
dc.subjectT/C polymorphism
dc.subjectprostate cancer risk
dc.subjectBreast-cancer
dc.subjectCyp17 Gene
dc.titleNo association of the 5 ' promoter region polymorphism of CVP17 gene with prostate cancer risk
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución